Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Asthma and Allergic Inflammation
share announcement

Asthma and Allergic Inflammation

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Clinical Immunology".

Deadline for manuscript submissions: closed (17 November 2023) | Viewed by 2838

Special Issue Editor

Dr. Corrado Pelaia

E-Mail Website
Guest Editor
Department of Health Sciences, University “Magna Græcia” of Catanzaro, Catanzaro, Italy
Interests: asthma; lung immunology; COPD and COVID-19
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Asthma and allergic diseases are public health issues worldwide and are challenges in the modern medical landscape. The condition is widespread, and often goes undiagnosed or inadequately, leading to many deaths. The impacts on clinical, economic and social affect healthcare systems in many countries and compromise the quality of life of patients. Although good treatments and a plethora of guidelines and strategies, no significant progress has been made in the past 20 years. These are multifactorial pathologies with genetic and environmental triggers and unique pathophysiological underlying dynamics. Their different cellular, molecular, and clinical characteristics make these diseases a true medical mystery that needs to be deciphered.

This Special Issue welcomes the submission of original articles, systematic reviews, communications and other types of articles on related topics. All manuscripts will follow standard journal peer-review practices, and those accepted for publication will appear in the “Asthma and Allergic Inflammation”. We look forward to receiving your contributions to the Special Issue.

Dr. Corrado Pelaia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • allergen immunotherapy
  • rhinitis
  • Epidemiology
  • personalized medicine
  • IgE
  • IL-5
  • IL-4
  • IL-13
  • monoclonal antibodies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

3 pages, 181 KiB  
Editorial
Special Issue on ‘Asthma and Allergic Inflammation’
by Corrado Pelaia
Vaccines 2023, 11(3), 531; https://doi.org/10.3390/vaccines11030531 - 23 Feb 2023
Cited by 1 | Viewed by 1012
Abstract
Asthma is a chronic inflammatory airway disease, driven by either allergic or non-allergic stimuli, which usually manifests as wheezing, reversible airflow limitation, and bronchial hyperresponsiveness [...] Full article
(This article belongs to the Special Issue Asthma and Allergic Inflammation)

Research

Jump to: Editorial

13 pages, 307 KiB  
Article
Real-World Safety and Efficacy Clinical Data of an Improved Allergen-Specific Immunotherapy Product for the Treatment of Bee Venom Allergy
by Luis Alfredo Gonzalez Guzman, Jose Carlos García Robaina, Javier Barrios Recio, Elena Escudero Arias, Tania Liñares Mata, Raquel Cervera Aznar, Federico De La Roca Pinzón, Lissette del Carmen Miguel Polo, Luis Arenas Villarroel, Verónica P. López Couso, Javier Alcover Diaz, David Rodriguez Gil, Ricardo Palacios Pelaez and Francisco Javier Carballada Gonzalez
Vaccines 2023, 11(5), 979; https://doi.org/10.3390/vaccines11050979 - 13 May 2023
Viewed by 1386
Abstract
The aim of this study is to explore the safety and efficacy of bee venom immunotherapy without HSA, in real-life patients. Methods: This is an observational retrospective study developed in seven hospitals in Spain, where patients treated with this immunotherapy were included. They [...] Read more.
The aim of this study is to explore the safety and efficacy of bee venom immunotherapy without HSA, in real-life patients. Methods: This is an observational retrospective study developed in seven hospitals in Spain, where patients treated with this immunotherapy were included. They gathered the protocol used to initiate the immunotherapy, adverse reactions, field re-stings, and the patient clinical data (clinical history, biomarkers, and skin prick test). Results: A total of 108 patients were included. In total, 4 protocols were used (5 weeks reaching 200 μg, and 4, 3, and 2 weeks reaching 100 μg). An incidence of systemic adverse reactions for each 100 injections of 1.5, 1.7, 0, and 0.58, respectively, was found. The demographic data showed not to directly affect the appearance of adverse reactions, except for those having a grade 2 systemic reaction with immunotherapy previously had a grade 4 systemic reaction; the IgE to Apis mellifera was 3 times higher in patients with systemic reactions of grade 1 than in the general group, and other specific IgEs were lower in those with systemic reactions. Most of the patients recognized Api m 1 followed by Api m 10. In the sample, 32% experienced spontaneous re-stings, without presenting systemic reactions, after a year of treatment. Full article
(This article belongs to the Special Issue Asthma and Allergic Inflammation)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop